These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37524201)

  • 1. Safety, tolerability, and pharmacokinetics of half-life extended SARS-CoV-2-neutralizing monoclonal antibodies AZD7442 (tixagevimab/cilgavimab) in healthy Japanese adults.
    Okada H; Ishikawa K; Itoh Y; Noda Y; Eto T; Pilla Reddy V; Chen CC; Gibbs M; Johnsson E
    J Infect Chemother; 2023 Nov; 29(11):1061-1067. PubMed ID: 37524201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.
    Forte-Soto P; Albayaty M; Brooks D; Arends RH; Tillinghast J; Aksyuk AA; Bouquet J; Chen C; Gebre A; Kubiak RJ; Pilla Reddy V; Seegobin S; Streicher K; Templeton A; Esser MT
    J Infect Dis; 2023 May; 227(10):1153-1163. PubMed ID: 36683419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
    Levin MJ; Ustianowski A; De Wit S; Launay O; Avila M; Templeton A; Yuan Y; Seegobin S; Ellery A; Levinson DJ; Ambery P; Arends RH; Beavon R; Dey K; Garbes P; Kelly EJ; Koh GCKW; Near KA; Padilla KW; Psachoulia K; Sharbaugh A; Streicher K; Pangalos MN; Esser MT;
    N Engl J Med; 2022 Jun; 386(23):2188-2200. PubMed ID: 35443106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials.
    Levin MJ; Ustianowski A; De Wit S; Beavon R; Thissen J; Seegobin S; Dey K; Near KA; Streicher K; Kiazand A; Esser MT
    Infect Dis Ther; 2024 Jun; 13(6):1253-1268. PubMed ID: 38703336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial.
    Hobbs FDR; Montgomery H; Padilla F; Simón-Campos JA; Arbetter D; Seegobin S; Kiazand A; Streicher K; Martinez-Alier N; Cohen TS; Esser MT
    Infect Dis Ther; 2024 Mar; 13(3):521-533. PubMed ID: 38403865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.
    Hobbs FDR; Montgomery H; Padilla F; Simón-Campos JA; Kim K; Arbetter D; Padilla KW; Reddy VP; Seegobin S; Streicher K; Templeton A; Viani RM; Johnsson E; Koh GCKW; Esser MT
    Infect Dis Ther; 2023 Sep; 12(9):2269-2287. PubMed ID: 37751015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19.
    Clegg LE; Stepanov O; Schmidt H; Tang W; Zhang H; Webber C; Cohen TS; Esser MT; Någård M
    Antimicrob Agents Chemother; 2024 May; 68(5):e0158723. PubMed ID: 38534112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 Infection.
    Bender Ignacio RA; Wohl DA; Arends R; Pilla Reddy V; Mu Y; Javan AC; Hughes MD; Eron JJ; Currier JS; Smith D; Chew KW; Gibbs M; Fletcher CV
    Clin Pharmacol Ther; 2022 Dec; 112(6):1207-1213. PubMed ID: 35797235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans.
    Loo YM; McTamney PM; Arends RH; Abram ME; Aksyuk AA; Diallo S; Flores DJ; Kelly EJ; Ren K; Roque R; Rosenthal K; Streicher K; Tuffy KM; Bond NJ; Cornwell O; Bouquet J; Cheng LI; Dunyak J; Huang Y; Rosenbaum AI; Pilla Reddy V; Andersen H; Carnahan RH; Crowe JE; Kuehne AI; Herbert AS; Dye JM; Bright H; Kallewaard NL; Pangalos MN; Esser MT
    Sci Transl Med; 2022 Mar; 14(635):eabl8124. PubMed ID: 35076282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.
    Levin MJ; Ustianowski A; Thomas S; Templeton A; Yuan Y; Seegobin S; Houlihan CF; Menendez-Perez I; Pollett S; Arends RH; Beavon R; Dey K; Garbes P; Kelly EJ; Koh GCKW; Ivanov S; Near KA; Sharbaugh A; Streicher K; Pangalos MN; Esser MT;
    Clin Infect Dis; 2023 Apr; 76(7):1247-1256. PubMed ID: 36411267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
    Montgomery H; Hobbs FDR; Padilla F; Arbetter D; Templeton A; Seegobin S; Kim K; Campos JAS; Arends RH; Brodek BH; Brooks D; Garbes P; Jimenez J; Koh GCKW; Padilla KW; Streicher K; Viani RM; Alagappan V; Pangalos MN; Esser MT;
    Lancet Respir Med; 2022 Oct; 10(10):985-996. PubMed ID: 35688164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials.
    Bender Ignacio RA; Chew KW; Moser C; Currier JS; Eron JJ; Javan AC; Giganti MJ; Aga E; Gibbs M; Tchouakam Kouekam H; Johnsson E; Esser MT; Hoover K; Neytman G; Newell M; Daar ES; Fischer W; Fletcher CV; Li JZ; Greninger AL; Coombs RW; Hughes MD; Smith D; Wohl DA;
    JAMA Netw Open; 2023 Apr; 6(4):e2310039. PubMed ID: 37099295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants.
    Tuffy KM; Ahani B; Aksyuk AA; Avila M; Brady T; Kijak GH; Koh G; Levin MJ; Roe TL; Schuko N; Thissen J; Ustianowski A; Zhang T; Kelly EJ; Streicher K
    J Infect Dis; 2023 Oct; 228(8):1055-1059. PubMed ID: 37280116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection.
    Kim JY; Jang YR; Hong JH; Jung JG; Park JH; Streinu-Cercel A; Streinu-Cercel A; Săndulescu O; Lee SJ; Kim SH; Jung NH; Lee SG; Park JE; Kim MK; Jeon DB; Lee YJ; Kim BS; Lee YM; Kim YS
    Clin Ther; 2021 Oct; 43(10):1706-1727. PubMed ID: 34551869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience.
    Pulvirenti F; Garzi G; Milito C; Sculco E; Sciannamea M; Napoli A; Cinti L; Roberto P; Punziano A; Carrabba M; Piano Mortari E; Carsetti R; Antonelli G; Quinti I
    Front Immunol; 2023; 14():1249462. PubMed ID: 37954618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy Adults.
    Aliprantis AO; Wolford D; Caro L; Maas BM; Ma H; Montgomery DL; Sterling LM; Hunt A; Cox KS; Vora KA; Roadcap BA; Railkar RA; Lee AW; Stoch SA; Lai E
    Clin Pharmacol Drug Dev; 2021 May; 10(5):556-566. PubMed ID: 33125189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial).
    Kijak GH; Ahani B; Arbetter D; Chuecos F; Gopalakrishnan V; Beloor J; Brady T; Nguyen A; Roe TL; Schuko N; Zhang T; Hobbs FDR; Padilla F; Kelly EJ; Montgomery H; Streicher K
    Infect Dis Ther; 2023 Dec; 12(12):2691-2707. PubMed ID: 37914983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults.
    Hao X; Zhang Z; Ma J; Cheng L; Ji Y; Liu Y; Zhao D; Zhang W; Li C; Yan L; Margolis D; Zhu Q; Zhang Y; Zhang F
    Front Pharmacol; 2022; 13():983505. PubMed ID: 36147329
    [No Abstract]   [Full Text] [Related]  

  • 19. Association Between AZD7442 (Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Hospitalization, and Mortality.
    Kertes J; Shapiro Ben David S; Engel-Zohar N; Rosen K; Hemo B; Kantor A; Adler L; Shamir Stein N; Mizrahi Reuveni M; Shahar A
    Clin Infect Dis; 2023 Feb; 76(3):e126-e132. PubMed ID: 35904210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, Safety, and Tolerability of Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Delivered Intravenously or Intramuscularly in Japanese and Caucasian Healthy Volunteers.
    Nader A; Alexander E; Brintziki D; Haggag AZ; Harrison SA; Hawes IA; Hezareh M; Lippa AM; Okamasa A; Okour M; Okuda N; Sager JE; Segal S; Shida Y; Skingsley A; Williams R; Yoon EY; Austin D
    Clin Pharmacokinet; 2024 Jan; 63(1):57-68. PubMed ID: 37955825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.